公司资料
Amylyx 股价、新闻与催化剂
- 股票代码:
- AMLX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
28.08 USD (-3.51%)
收盘价
最后更新: 2026年10月1日
1.48B USD
市值
股价为何变动
截至 2026年10月1日，AMLX 下跌 3.51%，收于 $28.08。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Neuroendocrine and Rare-Disease Biotechnology Company
Amylyx Pharmaceuticals develops therapies for endocrine and neurological diseases with limited treatment options. Its portfolio combines peptide therapeutics, antisense oligonucleotides, and small-molecule approaches across post-bariatric hypoglycemia, amyotrophic lateral sclerosis, Wolfram syndrome, and related disorders.
Avexitide and Post-Bariatric Hypoglycemia
Avexitide is a GLP-1 receptor antagonist designed to reduce the excessive insulin response that drives post-bariatric hypoglycemia. It is the company's lead late-stage asset and has received Breakthrough Therapy designation for both post-bariatric hypoglycemia and congenital hyperinsulinism.
Neurology Programs
AMX0114 is an antisense oligonucleotide targeting calpain-2 for amyotrophic lateral sclerosis. The program is in first-in-human development and reflects Amylyx's effort to build a mechanistically differentiated neurology pipeline beyond its earlier commercial history.
Wolfram Syndrome Development
AMX0035 is being studied in Wolfram syndrome, a rare genetic disorder affecting pancreatic beta cells, vision, and neurological function. Open-label clinical findings have supported continued discussions with the FDA regarding a potential Phase 3 study.
Next-Generation Endocrine Pipeline
AMX0318 is a long-acting GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia and other rare endocrine diseases. Amylyx is using external research collaborations to identify additional peptide candidates and broaden its endocrine portfolio.
未来催化剂
- Topline Phase 3 LUCIDITY data for avexitide in post-bariatric hypoglycemia in late August or early September 2026.
- Potential avexitide NDA submission and commercial launch in 2027, subject to positive data and regulatory review.
- IND filing for long-acting GLP-1 receptor antagonist AMX0318 in 2027.
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。